Retatrutide (development code LY3437943) represents a milestone in synthetic incretin pharmacology as a single 39-amino-acid peptide engineered with triple-agonist activity across the Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCG) receptors. Unlike single or dual incretin mimetics, the structural backbone of Retatrutide integrates a modified GIP peptide sequence with non-coded alpha-aminoisobutyric acid (Aib) residues and a C20 diacid fatty acyl side-chain conjugated via an AEEA linker to facilitate reversible albumin binding.
In recombinant human receptor expression assays, Retatrutide demonstrates potent, balanced nanomolar binding affinities:
In diet-induced obese (DIO) murine and primate models, continuous receptor occupancy by Retatrutide induced significant dose-dependent reductions in body weight exceeding dual GLP-1/GIP agonists. Notably, energy expenditure assessments via indirect calorimetry demonstrated that the sustained weight modulation was driven not solely by hypophagia, but critically through increased oxygen consumption and brown adipose tissue (BAT) thermogenesis mediated via the glucagon pathway.
Magnetic resonance spectroscopy (1H-MRS) in preclinical trials revealed a marked down-regulation of de novo lipogenesis enzymes (SREBP-1c, FAS) in hepatocytes, coupled with enhanced mitochondrial beta-oxidation. As a consequence, liver fat content decreased by upwards of 80% without evidence of hepatocellular stress or enzyme elevation.
Retatrutide is synthesized as a lyophilized white crystalline cake. Reconstitution should be conducted using sterile Bacteriostatic Water (0.9% Benzyl Alcohol) at ambient room temperature (20°C to 25°C). To prevent shearing of tertiary structure, the diluent stream must be directed along the inner glass vial wall without vigorous agitation or vortexing. Reconstituted aliquots must be preserved at 2°C to 8°C, shielded from UV light, with chemical integrity maintained for up to 30 days.
